About Nurix Therapeutics, Inc. - Common stock (NRIX)
Nurix Therapeutics Inc is a biotechnology company focused on developing innovative therapies that leverage the power of the ubiquitin-proteasome system to selectively target and degrade disease-causing proteins. By harnessing advanced drug discovery techniques, Nurix aims to create precision medicines for serious diseases, including cancer and autoimmune disorders. The company's proprietary platform enables it to design small molecules that can modulate protein levels within cells, providing a novel approach to treatment that aims to improve patient outcomes through targeted and effective therapies. Read More
San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the initiation of its pivotal Phase 2 DAYBreak clinical study. This critical advancement focuses on bexobrutideg (NX-5948), an investigational Bruton's tyrosine kinase (BTK) degrader,
Nurix Therapeutics Q3 2025 results miss revenue and EPS estimates, triggering a stock drop. The biotech firm also announced pivotal trial plans for its lead drug candidate.
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.
